What is Earlens Corporation?
Earlens Corporation is a privately held medical technology firm dedicated to revolutionizing the hearing experience for individuals suffering from hearing loss. The company is best known for the Earlens Contact Hearing Solution, a breakthrough technology recognized as a TIME Top 100 Invention. Unlike traditional hearing aids, the Earlens system utilizes a small lens to vibrate the eardrum directly, replicating the natural hearing process to deliver superior sound quality and the broadest bandwidth currently available. This nonsurgical, FDA-cleared solution represents a significant shift in how hearing impairment is managed, positioning the company at the intersection of advanced bio-engineering and consumer health technology.
How much funding has Earlens Corporation raised?
Earlens Corporation has raised a total of $221M across 9 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Unspecified
$500K
Debt
$6.2M
Series B
$40M
Debt
$45M
Debt
$2M
Series C
$73M
Debt
$45M
Private Equity (2010): $4.6M, investors not publicly disclosed
Series A (2010): $4.6M, investors not publicly disclosed
Unspecified (2011): $500K, investors not publicly disclosed
Debt (2013): $6.2M, investors not publicly disclosed
Series B (2014): $40M backed by Lightstone Ventures, New Enterprise Associates, and Aisling Capital
Debt (2017): $45M with participation from CRG LP
Debt (2020): $2M led by PPP
Series C (2022): $73M supported by Vertex Healthcare, SightLine Partners, Cochlear, RK Mellon, and Windham Venture Partners
Debt (2022): $45M featuring CRG
Key Investors in Earlens Corporation
CRG LP
CR Group L.P. is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and equity investments across life sciences and healthcare services.
SightLine Partners
Sightline Partners is an alternative investment manager specializing in secondary buyouts and joint venture transactions within high-quality medical technology and digital health sectors.
Cochlear
Cochlear is a global leader in implantable hearing solutions, designing and manufacturing advanced medical devices that restore hearing for individuals with moderate to profound hearing loss.
What's next for Earlens Corporation?
With the recent influx of capital, Earlens Corporation is well-positioned to scale its commercial operations and broaden the reach of its Contact Hearing Solution. The company's strategic roadmap likely involves deepening its market penetration, enhancing its manufacturing capabilities, and potentially exploring new clinical applications for its core vibration technology. As the firm transitions into this mature growth stage, the focus will remain on clinical efficacy and expanding the accessibility of its revolutionary hearing devices to a global patient population, supported by a robust network of healthcare-focused investors.
See full Earlens Corporation company page
